Chemoprevention: From research to clinical oncology

European Journal of Cancer

Volumn 41, Issue 13, 2005, Pages 1833-1841

  Veronesi, Umberto ^a   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast neoplasm; Chemoprevention; Clinical trials; Colorectal neoplasm; Prostate neoplasm

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BUDESONIDE; CALCIUM; CALCIUM CARBONATE; CELECOXIB; COLECALCIFEROL DERIVATIVE; DUTASTERIDE; ESTROGEN; EXEMESTANE; FENRETINIDE; FINASTERIDE; FOLIC ACID; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LETROZOLE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PELITINIB; POLYPHENOL DERIVATIVE; RALOXIFENE; RETINOL DERIVATIVE; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; SULINDAC; TAMOXIFEN; UNINDEXED DRUG;

ADENOMATOUS POLYP; ARTHRALGIA; BREAST CANCER; CANCER RISK; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FRACTURE; HUMAN; LIPIDOSIS; LUNG CANCER; META ANALYSIS; MOUTH CANCER; MUSCULOSKELETAL DISEASE; ONCOLOGY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 27644599027     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.06.007     Document Type: Article

References (85)

1. Lippman SM, Levin B. Cancer prevention: strong science and real medicine. J Clin Oncol 2005, 23, 249-253.
2. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 1998, 90(20), 1514-1528.
3. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002, 8, 314-346.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumour development. N Engl J Med 1988, 319, 525-532.
5. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997, 278, 1073-1077.
6. Braakhuis BJM, Tabor MP, Kummer JA, et al. A genetic explanation of slaughter's concept of field cancerization. Cancer Res 2003, 63, 1727-1730.
7. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353, 1993-2000.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90, 1371-1388.
9. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349, 215-224.
10. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342, 1946-1952.
11. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999, 340, 101-107.
12. Baron JA, Cole BF, Sandler RS, et al. A randomised trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348, 891-899.
13. Kelloff GJ, Sigman CC, Johnson KM, et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 2000, 9, 127-137.
14. Decensi A, Robertson C, Viale G, et al. A randomised trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003, 95, 779-790.
15. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995, 91, 2274-2282.
16. Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer 2004, 111(3), 418-423.
17. Wedren S, Lovmar L, Humphreys K, et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004, 6, R437-R449.
18. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001, 93, 1624-1632.
19. Boyd NF, Fishell E, Jong R, et al. Mammographic densities as a criterion for entry to a clinical trial of breast cancer prevention. Br J Cancer 1995, 72, 476-479.
20. Johnston Jr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomised, placebo-controlled trials. Arch Intern Med 2000, 160, 3444-3450.
21. Meyskens Jr FL, Surwit E, Moon TE, Childers JM, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomised trial. J Natl Cancer Inst 1994, 86, 539-543.
22. Mitchell MF, Hittelman WN, Hong WK, et al. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 1994, 3, 619-626.
23. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72, 1117-1130.
24. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002, 31, 33-36.
25. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361, 296-300.
26. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998, 352, 93-97.
27. Veronesi U, Maisonneuve P, Sacchini V, et al. Italian Tamoxifen Study Group. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002, 359, 1122-1124.
28. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352, 98-101.
29. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360, 817-824.
30. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281, 2189-2197.
31. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998, 90, 1461-1467.
32. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomised trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003, 95, 160-165.
33. Decensi A, Robertson C, Rotmensz N, et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br J Cancer 1998, 78, 572-578.
34. Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996, 7, 671-675.
35. Bonanni B, Serrano D, Cazzaniga M, et al. A biomarker trial of low-dose tamoxifen in HRT users. Proc Front Cancer Prev Res, 69. abstr A2.
36. Veronesi U, De Palo G, Marubini E, et al. Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999, 91, 1847-1856.
37. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
38. Goss PE, Ingle JN, Martine S, et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349, 1793-1802.
39. Coombes RC, Hall E, Gibson LJ, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350, 1081-1092.
40. The Big 1-98 Collaborative Group. Primary therapy of early breast cancer conference, St Gallen, Switzerland, 2005 abstr 54.
41. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992, 326, 658-662.
42. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348, 1467-1471.
43. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348(9040), 1472-1477.
44. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997, 89, 1406-1422.
45. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000, 11(4), 382-387.
46. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94, 252-266.
47. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328(18), 1313-1316.
48. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000, 342, 1149-1155.
49. MacLennan R, Macrae F, Bain C, et al. Randomised trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst 1995, 87(23), 1760-1766.
50. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst 1989, 81(17), 1290-1297.
51. Bonithon-Kopp C, Kronborg O, Giacosa A, et al. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000, 356(9238), 1300-1306.
52. Clark LC, Combs Jr GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomised controlled trial. Nutritional Prevention of Cancer Study Group. J AMA 1996, 276(24), 1957-1963.
53. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust 1995, 162(9), 491-493.
54. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomised controlled trial. J AMA 2002, 288(3), 321-333.
55. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomised controlled trial. JAMA 2004, 291(14), 1701-1712.
56. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002, 42, 55-80.
57. Shureiqi I, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000, 60(24), 6846-6850.
58. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333(10), 609-614.
59. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumours in a randomised trial. J Natl Cancer Inst 1993, 85(15), 1220-1224.
60. Sandler RS, Halabi S, Baron JA, et al. A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348(10), 883-890.
61. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003, 125(2), 328-336.
62. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50(6), 857-860.
63. Fiorucci S, Santucci L, Gresele P, et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003, 124(3), 600-607.
64. Williams JL, Nath N, Chen J, et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 2003, 63(22), 7613-7618.
65. Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 2003, 100(19), 10937-10941.
66. Cryer B, Kimmey MB. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 105(1B), 20S-30S.
67. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999, 96(13), 7563-7568.
68. Hawkey CJ. COX-2 inhibitors. Lancet 1999, 353(9149), 307-314.
69. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003, 149(6), 469-477.
70. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000, 10(5), 407-413.
71. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004, 172(4 Pt 1), 1314-1317.
72. Sudbø J, Lippman SM, Lee JJ, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004, 350(14), 1405-1413.
73. Mao L. Can molecular assessment improve classification of head and neck premalignancy? Clin Cancer Res 2000, 6(2), 321-322.
74. Sudbø J, Kildal W, Risberg B, et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001, 344(17), 1270-1278.
75. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315(24), 1501-1505.
76. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995, 332(21), 1405-1410.
77. Chiesa F, Tradati N, Grigolato R, et al. Randomised trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005, 115(4), 625-629.
78. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23(2), 254-266.
79. Sudbo J, Samuelsson R, Risberg B, et al. Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling. J clin Oncol 2005, 23(9), 1927-1933.
80. Beta Carotene Cancer Prevention Study Group The Alpha-Tocopherol. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330(15), 1029-35.
81. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334(18), 1150-1155.
82. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993, 11(7), 1216-1222.
83. van Zandwijk. Proc. ASCO 1999 Abstract no. 18.
84. Lee JS, Lippman SM, Benner SE, et al. Randomised placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994, 12(5), 937-945.
85. Lam S, leRiche JC, McWilliams A, Macaulay C, et al. A randomised phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004, 10(19), 6502-6511.